University of South Florida

Scholar Commons
Cell Biology, Microbiology, and Molecular Biology
Faculty Publications

Cell Biology, Microbiology, and Molecular Biology

1-27-2016

Identification of Novel Cyclic Lipopeptides from a
Positional Scanning Combinatorial Library with
Enhanced Antibacterial and Antibiofilm Activities
Nina Bionda
Torrey Pines Institute for Molecular Studies

Renee M. Fleeman
University of South Florida

César de la Fuente-Núñez
University of British Columbia

Maria C. Rodriguez
Torrey Pines Institute for Molecular Studies

Fany Reffuveille
University of British Columbia
See next page for additional authors

Follow this and additional works at: http://scholarcommons.usf.edu/bcm_facpub
Part of the Biology Commons, Cell Biology Commons, and the Microbiology Commons
Scholar Commons Citation
Bionda, Nina; Fleeman, Renee M.; de la Fuente-Núñez, César; Rodriguez, Maria C.; Reffuveille, Fany; Shaw, Lindsey N.; Pastar, Irena;
Davis, Stephen C; Hancock, Robert E W; and Cudic, Predrag, "Identification of Novel Cyclic Lipopeptides from a Positional Scanning
Combinatorial Library with Enhanced Antibacterial and Antibiofilm Activities" (2016). Cell Biology, Microbiology, and Molecular
Biology Faculty Publications. 32.
http://scholarcommons.usf.edu/bcm_facpub/32

This Article is brought to you for free and open access by the Cell Biology, Microbiology, and Molecular Biology at Scholar Commons. It has been
accepted for inclusion in Cell Biology, Microbiology, and Molecular Biology Faculty Publications by an authorized administrator of Scholar Commons.
For more information, please contact scholarcommons@usf.edu.

Authors

Nina Bionda, Renee M. Fleeman, César de la Fuente-Núñez, Maria C. Rodriguez, Fany Reffuveille, Lindsey
N. Shaw, Irena Pastar, Stephen C Davis, Robert E W Hancock, and Predrag Cudic

This article is available at Scholar Commons: http://scholarcommons.usf.edu/bcm_facpub/32

HHS Public Access
Author manuscript
Author Manuscript

Eur J Med Chem. Author manuscript; available in PMC 2017 January 27.
Published in final edited form as:
Eur J Med Chem. 2016 January 27; 108: 354–363. doi:10.1016/j.ejmech.2015.11.032.

Identification of novel cyclic lipopeptides from a positional
scanning combinatorial library with enhanced antibacterial and
antibiofilm activities

Author Manuscript

Nina Biondaa,§, Renee M. Fleemanb, César de la Fuente-Núñezc,†, Maria C. Rodrigueza,
Fany Reffuveillec, Lindsey N. Shawb, Irena Pastard, Stephen C. Davisd, Robert E. W.
Hancockc, and Predrag Cudica,*
aTorrey

Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, Florida
34987-2352, United States of America

bDepartment

of Cell Biology, Microbiology and Molecular Biology, University of South Florida,
4202 East Fowler Avenue, ISA2015, Tampa, Florida 33620-5150, United States of America
cDepartment

of Microbiology and Immunology, Centre for Microbial Diseases and Immunity
Research, 232-2259 Lower Mall Research Station, University of British Columbia, Vancouver,
BC, V6T 1Z4, Canada
dDepartment

of Dermatology and Cutaneous Surgery, University of Miami Miller School of
Medicine, Miami, Florida, United States of America

Author Manuscript

Abstract
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Treating bacterial infections can be difficult due to innate or acquired resistance mechanisms, and
the formation of biofilms. Cyclic lipopeptides derived from fusaricidin/LI-F natural products
represent particularly attractive candidates for the development of new antibacterial and
antibiofilm agents, with the potential to meet the challenge of bacterial resistance to antibiotics. A
positional-scanning combinatorial approach was used to identify the amino acid residues
responsible for driving antibacterial activity, and increase the potency of these cyclic lipopeptides.
Screening against the antibiotic resistant ESKAPE pathogens revealed the importance of
hydrophobic as well as positively charged amino acid residues for activity of this class of peptides.
The improvement in potency was especially evident against bacterial biofilms, since the lead
cyclic lipopeptide showed promising in vitro and in vivo anti-biofilm activity at the concentration
far below its respective MICs. Importantly, structural changes resulting in a more hydrophobic and
positively charged analog did not lead to an increase in toxicity toward human cells.
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1. Introduction
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Pathogens such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter sp.[1, 2]
(collectively called the ESKAPE pathogens) are the leading causes of hospital-acquired
infections, and are resistant to the most commonly used antibiotics due to their acquisition of
resistance genes, and their ability to form biofilms; leaving very few therapeutic options.[3,
4] The discovery of novel antibiotics has historically focused on bacteria growing in a
planktonic state, however it has recently been indicated that novel therapies addressing
bacterial infections must account for the presence of biofilms.[5, 6] It has been estimated
that bacterial biofilms are responsible for approximately 60–80% of all chronic infections.
[7] The important characteristic of chronic biofilm-associated infections is an insensitivity to
both the host immune response and antimicrobial intervention.[8–11] For example, bacteria
within a biofilm are up to 1,000 times more resistant to the effect of antibacterial agents than
the same organism circulating in a planktonic (free swimming) state.[12–14] Poor
penetration of the drug through the biofilm, slow growth of the biofilm due to nutrient
limitation, the activation of general stress response pathways, the emergence of a biofilmspecific phenotype and the presence of persister cells have been suggested as mechanisms of
biofilm resistance.[15–19] Chronic wounds, such as diabetic ulcers, pressure ulcers and
venous leg ulcers, are particularly susceptible to the development of biofilm-associated
infections due to impaired healing properties of patients.[20] These infections are typically
polymicrobial, with S. aureus and P. aeruginosa most frequently isolated from such
wounds.[21–23] In addition, A. baumannii has emerged as a significant nosocomial
pathogen, and is responsible for an increasing number of infections among
immunocompromised and trauma patients.[24–26] A number of antibiotics have been
evaluated for the prevention and disruption of biofilms, however few have proven to be
effective.[27, 28]
Eur J Med Chem. Author manuscript; available in PMC 2017 January 27.
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Although limited therapeutic options are presently available, in order to provide effective
treatments, new and innovative anti-infectives are needed, preferably with novel modes of
action and/or belonging to novel classes of drugs. To this end, the structurally unique LI-F
family of natural products, including fusaricidins, represent attractive candidates for the
discovery and development of new antibacterial agents, capable of treating complicated
infections caused by multidrug-resistant bacteria, including those found within biofilms.[29–
33] Fusaricidins/LI-Fs are cyclic lipodepsipeptide antifungal antibiotics isolated from
Paenibacillus sp. Amongst the isolated fusaricidin/LI-F antibiotics, fusaricidin A or LI-F04a
has been shown to possess the most potent in vitro antimicrobial activity, targeting a variety
of fungi and Gram-positive bacteria (MICs ranging from 0.78–3.12 μg/mL).[31, 32]
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Structural modifications of fusaricidin A/LI-F04a that include incorporation of a simpler
lipidic tail, and substitution of an ester bond with an amide bond, resulted in comparably
potent analogs, with improved proteolytic stability under physiologically relevant
conditions, and greatly decreased nonspecific cytotoxicity.[34] Structures of the most potent
fusaricidins/LI-Fs synthetic analogs, 1 and 2, are shown in Figure 1. In addition to being
active against planktonic Gram-positive bacteria, cyclic lipopeptides 1 and 2 showed
promising activity against bacterial biofilms as well. We have previously demonstrated that
1 and 2 very efficiently inhibit the growth of S. aureus biofilm in vitro, at concentrations
corresponding to their MICs, and that depsipeptide 1 reduced the proliferation of
community-associated MRSA (USA300) in an in vivo porcine wound model.[35] However,
depsipeptide 1 exhibited significant in vitro toxicity toward human liver and red blood cells.
[34] Although the mode of action of this class of antibacterial peptides is not yet fully
understood, the bacterial membrane has been suggested as a potential target based on
analysis of the Bacillus subtilis transcriptome after treatment with the fusaricidin/LI-F
natural product mixtures.[36] Our initial mechanistic studies showed that 1 and 2 are able to
depolarize the cytoplasmic membranes of Gram-positive bacteria in a concentrationdependent manner. However, a lack of correlation between membrane depolarization and
cell lethality suggested that membrane-targeting activity is not the primary mode of action
for this class of antibacterial peptides.[37] Due to its improved stability and lower
cytotoxicity, cyclic lipopeptide 2 may have significant advantages over naturally occurring
fusaricidin A/LI-F04a and its depsipeptide analogs as a lead structure for the development of
new antibacterial agents. In addition, amide analogs are synthetically more accessible than
the parent depsipeptides, allowing for further structural optimization using a combinatorial
chemistry approach. Indeed, given the 20 amino acid building blocks, even small cyclic
peptides such as 2 offer enormous diversity, and the potential for discovery of more potent
analogs. Among combinatorial chemistry strategies, positional scanning synthetic
combinatorial libraries (PS-SCL) offer a unique and rapid approach for peptide sequence
optimization.[38–40]
In the pilot study reported herein, we have generated a positional scanning combinatorial
library of cyclic lipopeptide 2, containing 130,321 cyclic lipopeptides to screen for enhanced
antibacterial activity. A lead cyclic lipopeptide was identified and assessed for its
antibacterial/antibiofilm activities and nonspecific toxicity.
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2. Results and discussion
To gain further insight into the amino acid requirements for antibacterial activity and
toxicity of the fusaricidin/LI-F class of cyclic lipopeptides, and to identify analog(s) with
improved activities, we prepared a combinatorial library of cyclic lipopeptide 2. Cyclic
lipopeptide 2 was used as a model compound due to its low nonspecific toxicity, promising
antibacterial/antibiofilm activities, and ease of synthesis.
2.1. Library design and synthesis
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The general strategy for cyclic lipopeptide combinatorial library preparation and library
deconvolution is outlined in Scheme 1. The cyclic lipopeptide synthetic combinatorial
library was generated by the process of divide, couple and recombine (tea bag“ method)
using a previously developed Fmoc SPPS chemistry.[34, 41, 42] In brief, our synthetic
strategy included attachment of the C-terminal amino acid Fmoc-D-Asp5-OAllyl to a PEGbased amide resin via the side chain, use of a combination of orthogonal protecting groups,
stepwise solid-phase assembly of a linear precursor, attachment of a lipidic tail followed by
coupling of the N-terminal Fmoc-Dap1(Mtt)-OH and on-resin cyclization. To maintain the
same order of D- and L-amino acids as they appear in the sequences of the fusaricidin/LI-F
natural products in the synthesized cyclic lipopeptides, D-Val2, D-Thr4, and D-Ala6 were
replaced with D-amino acid mixtures, whereas L-Val3 was similarly replaced with an Lamino acid mixture. Fmoc deprotection, amino acid coupling reactions and final cyclization
steps were monitored by a ninhydrin colorimetric test.[43, 44] As depicted in Scheme 1, four
sets of 19 cyclic lipopeptide sub-libraries (Cys is omitted because of its propensity to form
disulfide bonds) were prepared. The first set of 19 sub-libraries had specifically defined
amino acids in position 4 of the sequence (one of the 19 commercially available D-amino
acids), whereas the remaining three positions consisted of mixtures of the 19 D- or 19 Lamino acids. The next set of cyclic peptide sub-libraries were defined by the amino acid in
position 3 (one of the 19 commercially available L-amino acids), and the remaining
positions contained all possible amino acid combinations. This process was thus repeated for
the remaining amino acid residues. Variable positions were incorporated by coupling of a
mixture of 19 Fmoc-protected amino acids in predetermined molar ratios to compensate for
different coupling rates.[42] Protocols for the removal of Allyl and Mtt protecting groups,
on-resin cyclization, and cleavage of cyclic lipopeptide mixtures from the resin were
identical to those previously described for the synthesis of cyclic lipopeptide 2.[34, 37]
Using a PS-SCL approach, we generated a combinatorial library containing 130,321 cyclic
lipopeptides.
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2.2. Library screening and assessment antibacterial and antibiofilm activities of individual
peptides
To demonstrate the feasibility of the PS-SCL approach to identify novel cyclic lipopeptides
with improved antibacterial and antibiofilm activities, we screened the cyclic lipopeptide
library for activity against the ESKAPE pathogens. Screening assays were performed
according to standard microbroth dilution methods, using a tier of three different
concentrations (100, 50 and 25 μg/mL) in 96-well plates.[45, 46] As indicated from
screening assays, Figure 2, the sequences of cyclic lipopeptides for activity against both
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Gram-positive and Gram-negative bacteria were identified to contain neutral and positively
charged Lys and/or Arg amino acids. Therefore, we synthesized the nine peptides with
sequences shown in Figure 1. Cyclic lipopeptides 1, 2 and linear lipopeptide 13 were used
for comparison purposes.

Author Manuscript

All individual peptides 1–13 were synthesized as described previously.[34, 37] The
antibacterial in vitro activity of peptides 1–13 against ESKAPE pathogens was assessed in
an identical fashion as above, and those data are shown in Table 1. Cyclic lipopeptide 3 was
active against all ESKAPE pathogens at 110 μM (100 μg/mL); whereas at a much lower
concentration of 28 μM (25 μg/mL), this peptide exhibits antibacterial activity against VRE,
MRSA and A. baumannii. In addition, cyclic lipopeptide 3 was active against MRSA and P.
aeruginosa at 22 μM (20 μg/mL) and 55 μM (50 μg/mL) respectively. In comparison to
depsipeptide 1 and parent amide 2, these data demonstrate significant extension of the
antibacterial spectrum of 3.
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As shown in Table 1, depsipeptide 1 was active against VRE and MRSA at concentrations
of 30 μM (25 μg/mL) and 12 μM (10 μg/mL), respectively, whereas amide 2 at 62 μM (50
μg/mL) showed activity only against MRSA. Among other synthesized cyclic lipopeptides,
4 exhibits activity against VRE, MRSA and A. baumannii at 36 μM (35 μg/mL) and against
K. pneumoniae at 52 μM (50 μg/mL). No activity against P. aeruginosa and E. cloacae was
observed for this peptide at concentrations ≤104 μM (100 μg/mL), as shown in Table 1. All
other cyclic lipopeptides 5–12 did not show appreciable antibacterial activity against the
tested ESKAPE pathogens. Possible synergy of multiple peptides present in mixtures (76
mixtures each composed of 6,859 cyclic lipopeptides) containing these peptides may explain
the observed antibacterial activity for mixtures, as well as loss of activity in the case of the
individual peptides,[47, 48] More accurate identification of amino acids that drive
antibacterial activity of the described cyclic lipopeptides can be achieved by synthesis and
screening of a less complex, second generation PS-SCL composed only of the identified
hydrophobic and positively charged residues, thus reducing the possibility for synergistic
effect. Quite interestingly, an increase in a peptide’s cationicity, as exemplified by peptides
7 and 10, did not improve antibacterial activity. This observation is consistent with the
literature, and suggests that the balance of charge and hydrophobicity is delicate, and has to
be determined for each class of antimicrobial peptide.[49] Taking into consideration that
peptide 3 exhibits the most broad and potent antibacterial activity in this series of cyclic
lipopeptides, we selected it for further studies.
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In the case of cyclic lipopeptide 3, the greatest improvement in activity was observed against
bacterial biofilms. The in vitro ability of peptides 1–3 to decrease the number of cells within
biofilms, and disrupt mature 2-day old biofilms formed by MRSA and P. aeruginosa, was
assessed using flow cell chamber methodology, as described previously.[50] In each
experiment, all cells within biofilms were stained green with the fluorescent dye Syto-9, and
dead cells were stained red with propidium iodide (merge shown as yellow to red) for
subsequent visualization using confocal microscopy. Representative confocal microscopy
reconstructed images of S. aureus and P. aeruginosa biofilms untreated or treated with
cyclic lipopeptodes 1–3 are shown in Figure 3. The most potent activity against biofilms
formed by both organisms was observed for cyclic lipopeptide 3. Treatment with 3 at a
Eur J Med Chem. Author manuscript; available in PMC 2017 January 27.
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concentration of 4 μg/mL resulted in complete inhibition of biofilm formation, as well as
complete eradication of mature biofilms formed by both bacterial species. As shown in
Figure 3, depsipeptide 1 at 4 μg/mL was comparably effective in prevention and eradication
of Gram-positive (S. aureus) biofilms, whereas this peptide was slightly less effective
against Gram-negative (P. aeruginosa) biofilms. Conversely, the parent amide 2 at the same
concentration was able to prevent biofilm formation by S. aureus and P. aeruginosa, but was
unable to completely eradicate existing biofilms of these two organisms. Even though amide
2 did not eradicate mature S. aureus biofilms, it did substantially trigger biofilm cell death
under these conditions, as shown by the bacterial uptake of propidium iodide that stains cells
red (merged with Syto-9 shows as yellow) in Figure 3. The observed improved antibiofilm
activity of 3 is consistent with its activity against bacteria in a planktonic state and can be
attributed to an increase in the peptide’s overall hydrophobicity and cationicity relative to
the parent peptide 2. The more hydrophobic and cationic cyclic lipopeptide 3 more
efficiently penetrates into bacterial biofilm matrices and consequently more effectively
reduces bacterial viability.
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We and others have shown that substitution of D-Ala6 residue with either Gly6 or L-Ala6
causes a significant loss in antimicrobial activity of the fusaricidin/LI-F class of cyclic
lipopeptides.[34, 51] However, the fact that cyclic lipopeptide 3 with D-Lys in position 6
exhibits improved antibacterial activity, suggests that incorporation of a positively charged
amino acid into the sequence of fusaricidin/LI-F cyclic lipopeptides is well tolerated. This
finding is of particular practical significance for further optimization of cyclic lipopeptide 3
and related peptides, considering that the net charge, and the number of positively charged
residues, has been strongly correlated with biological activity for antimicrobial peptides.[52,
53] Predictably, control linear peptide 4 did not show activity against any of the ESKAPE
bacteria, Table 1, supporting our previous study that indicated the importance of the cyclic
structure for antibacterial activity.[34]
2.3. In vitro assessment of the potential for resistance development to 3
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Serial exposure of bacteria to antibacterial agents can be used to assess the propensity of an
organism to develop resistance.[54] Therefore, we investigated the potential of 3 to select
for resistance by initially passaging bacteria at sub-inhibitory concentrations, and then
increasing this by 2-fold each day. MRSA and P. aeruginosa were selected for these studies
as representative Gram positive and Gram-negative species because of the promising
inhibitory activity demonstrated thus far. In addition, these strains are clinical isolates, and
drug resistance amongst these organisms is wide-spread, substantially limiting available
treatment options. Vancomycin and ciprofloxacin were used as reference antibiotics. After
eight passages, the MIC of 3 increased approximately 8-fold against MRSA and P.
aeruginosa, Figure 4. In contrast, under the same experimental conditions, MICs obtained
for vancomycin and ciprofloxacin increased 64-fold in both tested bacteria. These findings
demonstrate limited ability of our clinical, broadly drug-resistance isolates, to develop
resistance towards the cyclic lipopeptides, compared to clinically relevant antibiotics. As
such, this indicates the potential for very low rates of resistance development to 3, and
related cyclic lipopeptides.
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2.4. Cytotoxicity
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It has been well established in the literature that the net positive charge (which facilitates
interaction with anionic phospholipids in the bacterial membrane), conformational flexibility
(allowing transition from a given peptides solution conformation to its active conformation),
hydrophobicity and amphipathicity (required for membrane penetration) are major factors
that affect the activity of antimicrobial peptides.[55–57] However, the enhancement of
hydrophobicity and cationicity can decrease selectivity between bacterial and human cells.
[57] Incorporation of more hydrophobic amino acids such as Leu and Ile, and positively
charged Lys into the cyclic lipopeptide sequence, increased its overall hydrophobicity and
net positive charge. In the case of cyclic lipopeptides 1–3, the relative overall
hydrophobicity order was 2<1<3, as indicated by their HPLC retention times (15.1, 15.8 and
16.9 min, respectivly). Since 3 is the most hydrophobic cyclic lipopeptide in the series, as a
measure of toxicity, the hemolysis of human erythrocytes and toxicity towards BJ human
skin fibroblasts induced by 3 was assessed.
Hemolytic activity was determined against human erythrocytes (0.5 % in PBS), Figure 5.
PBS and 1 % Triton X-100 were used as controls for 0 and 100 % hemolysis, respectively.
Despite the increase in hydrophobicity and positive charge in comparison to 1 or 2, cyclic
lipopeptide 3 did not show hemolytic activity at the highest tested concentration of 564 μM
(512 μg/mL), Figure 5. In comparison, low hemolytic activity was reported for cyclic
lipopeptide 2, as no appreciable hemolysis was observed at a concentration of 320 μM (260
μg/mL), whereas cyclic lipodepsipeptide 1 was shown to be highly hemolytic at a
concentration of 155 μM (128 μg/mL).[34] DMSO (1% v/v final concentration) used to
solubilize cyclic lipopeptide 3 did not cause hemolysis under the conditions described in the
Experimental Section.
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Toxicity of cyclic lipopeptides 1–3 toward human BJ cells is shown in Figure 6. The known
cytotoxic drug doxorubicin (Adriamycin) and 20% DMSO were used as positive and
negative controls in these assays. Low toxicity of 2 and 3 was observed against BJ cells;
with inordinately high concentrations required for both peptides 2 (250 μM, 203 μg/mL) and
3 (250 μM, 227 μg/mL) to induce a significant loss in cell viability. In contrast, no viable
cells were detected in cultures after incubation with depispeptide 1 at a concentration of 150
μM (124 μg/mL). This is consistent with our previous finding, showing lower cytotoxicity of
cyclic lipopeptides (amide analogs) in comparison to their depsipeptide counterparts.[34]
2.5. In vivo study
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The ability of cyclic lipopeptide 3 to reduce the proliferation of A. baumannii was assessed
in a porcine model of deep partial thickness wound, Figure 7. Wound infections caused by
this pathogen are difficult to treat due to a high level of resistance to multiple antibiotics and
its capacity to form a biofilm.[58] In addition, the recent reports indicated an increasing
identification of A. baumannii from wound, skin and soft-tissue infections,[24, 25] with a
higher incidence rate among hospitalized patients and injured military service members.[26]
Swine were chosen for this experiment due to the morphological and biochemical similarity
with human skin.[59]
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Wounds were inoculated with 25 μL of 106 CFU/mL of A. baumannii immediately after
treatment application and covered with a polyurethane film dressing to allow for biofilm
formation as previously described.[60] Infected wounds were treated with cyclic lipopeptide
3 at concentrations of 5.5, 11, 22 mM (5, 10, and 20 mg/mL), DMSO solutions. As shown in
Figure 6, peptide 3 reduced the number of A. baumannii in wounds in a concentrationdependent manner. At the highest tested concentration of 22 mM (20 mg/mL), a decrease of
approximately 3 log-units in the number of viable A. baumannii in comparison to untreated
wound was observed, indicating an antimicrobial effect of cyclic lipopeptide 3 on A.
baumannii in vivo. The same effect on A. baumannii was observed upon wound treatment
with silver sulfadiazine (1% cream), widely used to prevent and treat wound infections in
patients. Importantly, cyclic lipopeptide 3 at 22 mM (20 mg/mL) does not exhibit any
observable adverse effects, which is consistent with the low toxicity observed for this
peptide in the in vitro experiments.
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3. Conclusion
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In summary, we have demonstrated that modifying the amino acid sequences of cyclic
lipopeptides belonging to the fusaricidin/LI-F class of antimicrobial peptides seemingly
leads to analogs with improved anibacterial/antibiofilm activities and markedly decreased
nonspecific toxicity. The sequence of cyclic lipopeptide 2 was modified in a positional
scanning format, allowing for the rapid identification of amino acid residues responsible for
driving antibacterial activity at each position. Of note, screening against the ESKAPE
pathogens revealed the importance of hydrophobic as well as positively charged amino acid
residues for activity of this class of antibacterial peptides. An increase in overall
hydrophobicity of cyclic lipopeptides, and their net positive charge, resulted in improved
antibacterial activity. This improvement is particularly important for activity against
bacterial biofilms, as the lead peptide 3 showed potent broad-spectrum antibiofilm activity.
In contrast to the parent cyclic lipopeptide 2, peptide 3 at a concentration of 4.4 μM (4
μg/mL) effectively inhibited biofilm formation and was able to fully eradicate mature
biofilms formed by both MRSA and P. aeruginosa. In addition, a serial passage in vitro
resistance development study shows that peptide 3 has a low propensity to select for
resistance compared with vancomycin and ciprofloxacin. Promising in vivo antibacterial
activity of 3 was demonstrated by prevention of A. baumannii growth in a porcine model of
deep partial thickness wounds. Importantly, structural changes resulting in an increase of
overall hydrophobicity and cationicity did not lead to increased nonspecific toxicity. By
identifying peptide 3 possessing amino acid sequences that are not found in either the parent
peptide 2, or in any of the fusaricidin/LI-F natural products, we have demonstrated that our
approach may go beyond fusaricidin/LI-F natural product sequences in the discovery of
novel and more potent antibacterial peptides of this class.
Clearly, our findings warrant further investigation of the fusaricidin/LI-F class of cyclic
lipopeptide structure-activity relationship and their modification to find the optimal balance
between antibacterial activity and toxicity. Synthesis of additional cyclic lipopeptides based
on our screening assay against ESKAPE bacteria, and assesment of their antibacterial/
antibiofilm activities and toxicity, is currently underway by our group.
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4. Experimental section
4.1. Materials and methods
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TentaGel XV RAM resin was obtained from Rapp Polymere, GmbH. (Tuebingen,
Germany). Fmoc-protected amino acids and coupling reagents (HOBt, HBTU, PyBOP) were
purchased from Chem-Impex (Wood Dale, IL, USA). N-methylmorpholine, triethylamine
and Pd(PPh3)4 was purchased from Sigma-Aldrich (St. Louis, MO, USA). All solvents were
purchased from Sigma–Aldrich, and were analytical reagent grade or better. Individual
peptides were synthesized on a PS3 automated peptide synthesizer (Protein Technologies
Inc., Tucson, AZ, USA). Mass spectrometry was performed on MALDI-TOF Voyager-DE
STR (Applied Biosystems, Foster City, CA, USA) in reflector mode using α-cyano-4hydroxycinnamic acid as a matrix and positive mode. Analytical RP-HPLC analyses and
peptide purifications were performed on 1260 Infinity (Agilent Technologies, Santa Clara,
CA, USA) liquid chromatography systems equipped with a UV/Vis detector. For analytical
RP-HPLC analysis, a C18 monomeric column (Grace Vydac, 250 × 4.6 mm, 5 mm, 120 Å),
1 mL/min flow rate, and an elution method with a linear gradient of 2–98 % B over 30 min,
where A is 0.1 % TFA in H2O, and B is 0.08 % TFA in CH3CN were used. For peptide
purification, a preparative C18 monomeric column (Grace Vydac, 250 × 22 mm, 10 mm,
120 Å) was used. Elution method was identical to the analytical method except for the flow
rate, which was 19 mL/min. Cytotoxicity assays were analyzed on a Synergy H4 microplate
reader (BioTek, Winooski, VT, USA). The ESKAPE pathogen isolates (VancomycinResistant E. faecium strain USF-1449, Methicillin-Resistant S. aureus strain CBD-635, K.
pneumoniae strain USF-1433, A. baumannii strain USF-1403, P. aeruginosa strain
USF-1423 and E. cloacae strain USF-1454) used for MIC and resistance testing have been
described by us previously.[61] A. baumannii (ATCC 19606) used in the in vivo study and
human skin fibroblasts BJ (ATCC CRL-2522) cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA). S. aureus (MRSA, #SAP0017) and P.
aeruginosa (reference strain PA14) used in the flow cell experiments were obtained from the
UBC collection. Dehydrated culture media and polystyrene plates (BD 353072 Falcon) used
for antimicrobial and human cell toxicity assays were purchased from Becton Dickinson
(Franklin Lakes, NJ, USA). Microscopy was performed using a Leica DMI 4000 B widefield fluorescence microscope (Leica Microsystems Inc., Buffalo Grove, IL, USA). Control
antibiotics were purchased from Sigma–Aldrich. Human red blood cells (hRBCs) were
purchased from Innovative Research (Novi, MI, USA). A young female specific-pathogenfree Yorkshire pig was purchased from Looper Farms (NC, USA). Tegaderm polyurethane
film dressing was purchased from 3M Health Care (St. Paul, MN, USA).
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4.2. General procedure for peptide synthesis and purification
Cyclic lipopeptide PS-SCL and individual peptides 1–13 were synthesized on amide
TentaGel XV RAM resin (substitution 0.26 mmol/g, 0.025 mmol scale) using standard
Fmoc solid-phase chemistry as reported previously.[34, 37] In all cases the solid-phase
synthesis started by attaching C-terminal Fmoc-D-Asp-OAllyl via side chain to the resin
using HBTU/HOBt/NMM protocol. The same coupling protocol was used throughout,
including coupling of the lipidic tail (Fmoc-12-aminododecanoic acid, 1.5 eq). In the case of
depsipeptide 1, Alloc-D-Ala-OH (4 eq) was coupled via ester bond to the hydroxyl group of
Eur J Med Chem. Author manuscript; available in PMC 2017 January 27.
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Fmoc-Thr using N,N′-diisopropylcarbodiimide (DIC, 4 eq.) and 4-dimethylaminopyridine
(DMAP, 1 eq) coupling reagents in CH2Cl2. PS-SCL and peptides 2–13 were prepared by
coupling Fmoc-Dap(Mtt)-OH instead of Fmoc-Thr-OH using the same coupling protocol as
above. Selective removal of Allyl and Alloc protecting groups was performed by treatment
of peptidyl-resin precursors with borane dimethylamine complex (4 eq), followed by
addition of Pd(PPh3)4 (0.1 eq) in CH2Cl2 under argon. Mtt was selectively removed under
mild acidic conditions (1% trifluoroacetic acid in CH2Cl2, 30 min). Solid-phase cyclization
of linear precursors was carried out in a manual reaction vessel overnight using PyBOP/
HOBt/DIEA (2:2:6 eq) in DMF. The conversion of the lipid tail amino group into the
desired guanidino group was achieved by removal of the Fmoc protecting group using
standard piperidine deprotection protocol and treatment of the peptidyl-resin with N,N′-diBoc-N″-triflylguanidine (5 eq) and triethylamine (5 eq) in DCM as described previously.[62]
The final purity of synthesized peptides 1–13 was confirmed by analytical RP-HPLC, LC
ESI MS and MALDI TOF MS, and was ≥ 95% in all cases.
4.3. Screening of cyclic lipopeptide PS-SCL and assessment of antibacterial activities of
peptides 1–13

Author Manuscript

Screening of cyclic lipopeptide PS-SCL for activity against the ESKAPE pathogens was
performed using three different concentrations (100, 50, and 25 μg/mL) in sterile 96-well
flat-bottomed polystyrene plates according to the Clinical and Laboratory Standards Institute
(CLSI) guidelines.[45] Müller–Hinton broth (MHB) without dilution was used in this
experiment. The cyclic lipopeptide PS-SCL was solubilized in DMSO and appropriate
dilutions were made in media to a final 1% DMSO concentration (v/v). Controls on each
plate were media without bacteria, bacterial inoculum without antimicrobials added, and
bacterial inoculum containing methicillin, vancomycin, nisin, colistin and bacitracin.
Assessment of activities of peptides 1–13 against ESKAPE bacteria was completed in an
identical fashion to that described above. All experiments were performed in triplicate.
4.4. Hemolytic activity

Author Manuscript

Human red blood cells (hRBCs) were diluted in PBS to 1%. Cyclic lipopeptide 3 was
dissolved in 10% DMSO/H2O (v/v) solvent mixture to concentrations of 8.8–1128 μM (8–
1024 μg/mL). In each well of a clear, flat-bottom 96-well plate, 50 μL of hRBCs were
placed, followed by addition of 50 μL of cyclic lipopeptide solution, to a final peptide
concentration of 4.4–564 μM (4–512 μg/mL). Assays were performed in triplicate, and each
experiment was repeated twice. To determine the potential effect of DMSO on hemolytic
activity, controls containing 10 % DMSO in H2O (v/v) were added to the assay setup. As a
positive control, 50 μL Triton X-100 in H2O was used at a final concentration of 1 % (v/v).
As a negative control, 50 μL of PBS was used. Plates were incubated for 1 h at 37 °C. To
each well 100 μL of PBS was added, and the plates were centrifuged for 10 min at 1000 g.
Supernatants (150 μL) were transferred to a new plate, and absorbance at 405 nm was
measured. No effect of 10% DMSO in H2O on hemolysis of hRBCs was observed. The
degree of hemolysis of the cyclic lipopeptides was expressed in percent relative to the
hemolysis caused by Triton-X.
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4.5. Cytotoxicity
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Cytotoxicity of peptides 1–3 was determined using Cell Titer-Glo Luminescent Cell
Viability Assay (Promega). Assays were performed in flat-bottom polystyrene 96-well
plates with 10,000 BJ cells (ATCC CRL-2522) per well grown in EMEM containing 10%
FBS, and 5% penicillin/streptomycin (v/v). After overnight incubation at 37°C in a
humidified atmosphere with 5% CO2, media was removed, and replaced with fresh media
with 2% FBS containing peptides 1–3 in a concentration range of 0.5–500 μM. Peptides 1–3
were dissolved in DMSO, and appropriate dilutions were made in buffer to a final
concentration of 1% DMSO (v/v). Plates were again incubated at 37°C in a humidified
atmosphere with 5% CO2. As a control, 10 μM doxorubicin and 20% DMSO in H2O were
used. After incubation for 48 and 72 h, respectively, media was removed, and 100 μL PBS
buffer added, followed by 100 μL of Cell Titer-Glo Reagent. Plates were incubated for
further 10 min at room temperature (protected from light), before luminescence readout.
4.6. Flow cell experiments and biofilm imaging by confocal microscopy
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For inhibition studies, Pseudomonas aeruginosa PA14 and Staphylococcus aureus MRSA
(clinical isolate #SAP0017) biofilms were grown in BM2 minimal glucose medium for 72 h,
with and without the addition of cyclic lipopeptides 1–3 (final concentration of 4.4 μM (4
μg/mL) at 37°C in flow chambers as previously described.[50] In eradication studies,
bacteria were allowed to develop structured biofilms for 2 days prior to peptide treatment for
24 h. Silicone tubing (VWR, 0.062 in ID by 0.125 in OD by 0.032 in wall) was autoclaved,
and the system was assembled and sterilized by pumping a 0.5% hypochlorite solution
through the system at 6 rpm for 30 min using a Watson Marlow 205S multi-channel
peristaltic pump. The system was then rinsed with sterile water and medium for 30 min
each. Flow chambers were inoculated by injecting 400 μL of an overnight culture diluted to
an OD600 of 0.05. After inoculation, chambers were left without flow for 2 h to allow
bacteria to adhere to the surface of the flow cell chambers, after which medium was pumped
through the system at a constant rate of 0.5 rpm (2.4 mL/h). Biofilm cells were stained using
the LIVE/DEAD BacLight Bacterial Viability kit (Molecular Probes, Eugene, OR) prior to
microscopy experiments. A ratio of SYTO-9 (green fluorescence, live cells) to propidium
iodide (PI) (red fluorescence, dead cells) of 1:5 was used. Microscopy was done using a
confocal laser scanning microscope (Olympus, Fluoview FV1000) and three-dimensional
reconstructions were generated using the Imaris software package (Bitplane AG).
4.7. Serial passage experiment
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Serial passage was initiated from overnight cultures of MRSA CBD-635 and P. aeruginosa
USF-1423 grown in MHB to exponential growth phase and added to a fresh medium
containing cyclic lipopeptide 3 or the controls vancomycin and ciprofloxacin at
concentrations corresponding to ½ MICs. Final bacterial concentrations were approximately
106 CFU/mL. The bacteria were incubated overnight at 37°C and an aliquot was transferred
to a new tube with 2 fold increased concentration of 3 or control antibiotics. The process
was repeated for 8 passages. The MIC was determined at each step as described above.

Eur J Med Chem. Author manuscript; available in PMC 2017 January 27.

Bionda et al.

Page 12

4.8. Antibacterial activity in in vivo wound infection model
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Wounding and infection—A young female specific-pathogen-free pig was used. The
animal was fed a non-antibiotic chow ad libitum before the study, fasted overnight before
the procedures, and housed individually in our USDA-compliant animal facilities. The
experimental protocol was approved by the University of Miami Institutional Animal Care
and Use Committee, and all the procedures followed the federal guidelines for the care and
use of laboratory animals. Methods for the animal preparation and wounding are described
previously.[23, 63–65] Briefly, the flank and the back of experimental animals were prepped
on the day of the experiment. Animals were anesthetized and partial thickness wounds were
made on the paravertebral area using a modified electrokeratome set at 0.5 mm deep × 10
mm × 7 mm.[63] The wounds were separated from one another by approximately 4–6 cm
areas of unwounded skin. Wounds were inoculated with 25 μL of 106 CFU/mL of A.
baumannii (ATCC 19606). Wounds were treated within 20 min (after inoculation) with 200
μL of peptide 3 (5, 10 and 20 mg/mL; 5.5, 11, 22 mM), vehicle (DMSO) and silver
sulfadiazine (1% ointment, 150–200 mg/wound).. Control wounds were infected and no
treatment was applied. All wounds, including control, were covered with polyurethane film
dressing (Tegaderm) to maintain a moist environment, promote biofilm formation and
prevent any cross-contamination between wounds.[60]

Author Manuscript

Bacterial recovery—Three wounds from each treatment group were cultured
quantitatively using a modified scrub technique.[60] Each wound was encompassed by a
sterile surgical grade steel cylinder (22 mm outside diameter), and bacteria were collected
by scrubbing the wound area with a sterile Teflon spatula into 1 mL of sterile phosphate
buffer saline. Serial dilutions were made and plated using a Spiral Plate System, and Leeds
selective media was used to determine CFUs in the scrub solution collected from each
wound. Plated bacteria were incubated aerobically for 48 h at 37°C. CFUs were determined
by the standard colony counting method.
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HIGHLIGHTS
•

Positional-scanning combinatorial library of cyclic lipohexapeptides was
prepared.

•

Analogs with improved antibacterial activities were identified.

•

The improvement in activity was especially evident against bacterial biofilms.

•

Hydrophobic and positively charged amino acids are crutial for activity.

•

Resulting structural changes did not lead to an increase in nonselective toxicity.
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Figure 1.

Sequences of cyclic lipopeptides 1–12 and control lipopeptide 13.
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Figure 2.
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Screening of cyclic lipopeptide positional scanning-synthetic combinatorial library for
activity against the ESKAPE pathogens. Nineteen amino acids were tested for activity at
each of the four varying positions. A = R2; B = R3; C = R4; and D = R6. The height for each
individual bar is determined by dividing 100 μg/mL (the maximum concentration tested) by
the individual MIC for each agent against the respective pathogen. Libraries are then given a
scaled score for each pathogen, and these are then stacked to determine the amino acid that
displays the broadest activity, at the lowest concentration.
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Figure 3.
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Cyclic lipopeptides prevented biofilm formation and eradicated existing biofilms of Gramnegative and Gram-positive bacterial pathogens. Inhibition of biofilm formation was tested
by immediately adding 4.4 μM (4 μg/mL) of each cyclic lipopeptide 1–3 into the flowthrough medium of the flow cell apparatus, and subsequently monitoring biofilm formation
for a total of 3 days. Eradication experiments involved growing biofilms untreated for two
days before the addition of peptides into flow-through medium. After 3 days, all bacteria
were stained green with stain Syto-9, while dead-bacteria were stained red with propidium
iodide (merge shown as yellow to red) prior to confocal imaging. Each panel shows
reconstructions from the top in the large panel and sides in the right and bottom panels (xy,
yz and xz dimensions). (A to C) shows inhibition of biofilm formation. (D–F) shows
eradication of preformed biofilms. (G) shows untreated bacteria.
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Figure 4.
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Resistance acquisition during serial passaging in the presence of sub-MIC levels of
antimicrobials. (A) MRSA CBD-635 and (B) P. aeruginosa USF-1423. MICs are: a) cyclic
lipopeptide 3, 22 μM (20 μg/mL) for S. aureus and 55 μM (50 μg/mL) for P. aeruginosa; b)
vancomycin, 7 μM (10 μg/mL); c) ciprofloxacin, 30 μM (10 μg/mL). The figure is
representative of three independent experiments.
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Figure 5.

Hemolytic activity of cyclic lipopeptide 3. 100% hemolysis was determined by incubating
hRBCs with 1% Triton X.
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Figure 6.

Toxicity of cyclic lipopeptides 1–3 toward BJ human skin fibroblasts. Doxorubicin and
DMSO were used as positive controls. 1 (■), 2 (□), 3 ( ).
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Figure 7.

Effect of 3 on A. baumannii 19606 in vivo using a deep partial thickness porcine wound
model. A. baumannii CFUs were determined from porcine wounds 24h post infection and
topical treatment with 3 (n=3). Silver sulfadiazine was used as 1% cream.
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Positional scanning synthetic combinatorial library of cyclic lipopeptides. Each set contains
19 separate mixtures. (X) represents position composed of a mixture of 19 amino acids
(redox-sensitive Cys is omitted). (Y) represents position defined with an individual amino
acid.
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Activities of lipopeptides 1–13 and control antibiotics against ESKAPE pathogens.
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